News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DOR BioPharma, Inc. (DORB) Announces Named Patient Access Program for orBec(R) in Collaboration With Orphan Australia Pty Ltd


11/28/2007 3:36:15 PM

DOR BioPharma, Inc., (OTCBB: DORB) ("DOR" or the "Company") announced today that it has entered into a Letter of Intent with Orphan Australia Pty Ltd. (Orphan Australia), a specialty pharmaceutical company based in Melbourne, Australia, pursuant to which Orphan Australia will act as DOR's Sponsor with regard to the administration of a Named Patient Access Program (NPAP) for orBecĀ® to gastrointestinal Graft-versus-Host disease (GI GVHD) patients in Australia, New Zealand and South Africa.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES